| Title |
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
|
|---|---|
| Published in |
European Journal of Nuclear Medicine and Molecular Imaging, November 2016
|
| DOI | 10.1007/s00259-016-3573-4 |
| Pubmed ID | |
| Authors |
Frederik L. Giesel, B. Hadaschik, J. Cardinale, J. Radtke, M. Vinsensia, W. Lehnert, C. Kesch, Y. Tolstov, S. Singer, N. Grabe, S. Duensing, M. Schäfer, O. C. Neels, W. Mier, U. Haberkorn, K. Kopka, C. Kratochwil |
| Abstract |
The prostate-specific membrane antigen (PSMA) targeted positron-emitting-tomography (PET) tracer (68)Ga-PSMA-11 shows great promise in the detection of prostate cancer. However, (68)Ga has several shortcomings as a radiolabel including short half-life and non-ideal energies, and this has motivated consideration of (18)F-labelled analogs. (18)F-PSMA-1007 was selected among several (18)F-PSMA-ligand candidate compounds because it demonstrated high labelling yields, outstanding tumor uptake and fast, non-urinary background clearance. Here, we describe the properties of (18)F-PSMA-1007 in human volunteers and patients. Radiation dosimetry of (18)F-PSMA-1007 was determined in three healthy volunteers who underwent whole-body PET-scans and concomitant blood and urine sampling. Following this, ten patients with high-risk prostate cancer underwent (18)F-PSMA-1007 PET/CT (1 h and 3 h p.i.) and normal organ biodistribution and tumor uptakes were examined. Eight patients underwent prostatectomy with extended pelvic lymphadenectomy. Uptake in intra-prostatic lesions and lymph node metastases were correlated with final histopathology, including PSMA immunostaining. With an effective dose of approximately 4.4-5.5 mSv per 200-250 MBq examination, (18)F-PSMA-1007 behaves similar to other PSMA-PET agents as well as to other (18)F-labelled PET-tracers. In comparison to other PSMA-targeting PET-tracers, (18)F-PSMA-1007 has reduced urinary clearance enabling excellent assessment of the prostate. Similar to (18)F-DCFPyL and with slightly slower clearance kinetics than PSMA-11, favorable tumor-to-background ratios are observed 2-3 h after injection. In eight patients, diagnostic findings were successfully validated by histopathology. (18)F-PSMA-1007 PET/CT detected 18 of 19 lymph node metastases in the pelvis, including nodes as small as 1 mm in diameter. (18)F-PSMA-1007 performs at least comparably to (68)Ga-PSMA-11, but its longer half-life combined with its superior energy characteristics and non-urinary excretion overcomes some practical limitations of (68)Ga-labelled PSMA-targeted tracers. |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Morocco | 1 | 8% |
| Pakistan | 1 | 8% |
| Netherlands | 1 | 8% |
| Iraq | 1 | 8% |
| Spain | 1 | 8% |
| Canada | 1 | 8% |
| Turkey | 1 | 8% |
| Unknown | 5 | 42% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 50% |
| Scientists | 3 | 25% |
| Practitioners (doctors, other healthcare professionals) | 2 | 17% |
| Science communicators (journalists, bloggers, editors) | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 350 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| France | 1 | <1% |
| Germany | 1 | <1% |
| Unknown | 347 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 45 | 13% |
| Student > Master | 37 | 11% |
| Student > Bachelor | 32 | 9% |
| Student > Ph. D. Student | 31 | 9% |
| Other | 23 | 7% |
| Other | 68 | 19% |
| Unknown | 114 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 117 | 33% |
| Chemistry | 35 | 10% |
| Physics and Astronomy | 16 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 3% |
| Nursing and Health Professions | 8 | 2% |
| Other | 44 | 13% |
| Unknown | 121 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 April 2024.
All research outputs
#2,703,086
of 25,837,817 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#201
of 3,565 outputs
Outputs of similar age
#50,354
of 422,323 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#2
of 34 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,565 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 422,323 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.